Novel Therapies for the Treatment of Advanced Prostate Cancer

被引：15

作者：

Clarke, J. M. ^{[1
]}

Armstrong, A. J.

机构：

[1] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC 27710 USA

来源：

CURRENT TREATMENT OPTIONS IN ONCOLOGY | 2013年 / 14卷 / 01期

关键词：

Prostate cancer; Novel; Treatments; Castration-resistant; Androgen receptor; Metastatic; PI3 kinase inhibitors; Androgen synthesis inhibitors; Immunotherapies; Epigenetic; Epithelial mesenchymal transition; EPITHELIAL-MESENCHYMAL TRANSITION; RANDOMIZED PHASE-II; ANDROGEN RECEPTOR; TRANSGENIC ADENOCARCINOMA; BREAST-CANCER; DOUBLE-BLIND; DOCETAXEL; TRIAL; METASTASIS; SURVIVAL;

D O I：

10.1007/s11864-012-0222-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In recent years, great success has been achieved on many fronts in the treatment of men with metastatic castration-resistant prostate cancer (CRPC), including novel chemotherapeutics, immunotherapies, bone microenvironment-targeted agents, and hormonal therapies. Numerous agents are currently in early-phase clinical trial development for the treatment of advanced prostate cancer. These novel therapies target several areas of prostate tumor biology, including the upregulation of androgen signaling and biosynthesis, critical oncogenic intracellular pathways, epigenetic alterations, and cancer immunology. Importantly, the characterization of the prostate cancer genome offers the potential to exploit conserved genetic alterations, which may increase the efficacy of these targeted therapies. Predictive and prognostic biomarkers are urgently needed to maximize therapeutic efficacy and safety of these promising new treatments options in prostate cancer.

引用

页码：109 / 126

页数：18

共 94 条

[1] Novel Molecular Targets for the Therapy of Castration-Resistant Prostate Cancer [J].

Agarwal, Neeraj ;

Sonpavde, Guru ;

Sternberg, Cora N. .

EUROPEAN UROLOGY, 2012, 61 (05) :950-960

[2] Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor [J].

Andersen, Raymond J. ;

Mawji, Nasrin R. ;

Wang, Jun ;

Wang, Gang ;

Haile, Simon ;

Myung, Jae-Kyung ;

Watt, Kate ;

Tam, Teresa ;

Yang, Yu Chi ;

Banuelos, Carmen A. ;

Williams, David E. ;

McEwan, Iain J. ;

Wang, Yuzhou ;

Sadar, Marianne D. .

CANCER CELL, 2010, 17 (06) :535-546

[3]

[Anonymous], J CLIN ONCOL S

[4]

[Anonymous], N ENGL J MED

[5]

[Anonymous], 2012 EUROPEAN SOCIET

[6] Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer [J].

Antonarakis, E. S. ;

Armstrong, A. J. .

PROSTATE CANCER AND PROSTATIC DISEASES, 2011, 14 (03) :206-218

[7] Dasatinib combined with docetaxel for castration-resistant prostate cancer [J].

Araujo, John C. ;

Mathew, Paul ;

Armstrong, Andrew J. ;

Braud, Edward L. ;

Posadas, Edwin ;

Lonberg, Mathew ;

Gallick, Gary E. ;

Trudel, Geralyn C. ;

Paliwal, Prashni ;

Agrawal, Shruti ;

Logothetis, Christopher J. .

CANCER, 2012, 118 (01) :63-71

[8] Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin [J].

Armstrong, Andrew J. ;

George, Daniel J. ;

Halabi, Susan .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) :3402-3407

[9] Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer [J].

Armstrong, Andrew J. ;

Eisenberger, Mario A. ;

Halabi, Susan ;

Oudard, Stephane ;

Nanus, David M. ;

Petrylak, Daniel P. ;

Sartor, A. Oliver ;

Scher, Howard I. .

EUROPEAN UROLOGY, 2012, 61 (03) :549-559

[10] Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers [J].

Armstrong, Andrew J. ;

Marengo, Matthew S. ;

Oltean, Sebastian ;

Kemeny, Gabor ;

Bitting, Rhonda L. ;

Turnbull, James D. ;

Herold, Christina I. ;

Marcom, Paul K. ;

George, Daniel J. ;

Garcia-Blanco, Mariano A. .

MOLECULAR CANCER RESEARCH, 2011, 9 (08) :997-1007

← 1 2 3 4 5 6 7 8 9 10 →